Elucigene TRP-Fplus

Venous Thrombosis causes an estimated 50,000 deaths per year in the US and has an incidence of 1 per 1000 annually. There are many reported risk factors including a genetic element that can contribute to thrombosis. Cardiovascular disease is a leading cause of death for both men and women in most racial ethnic groups.

Elucigene TRP-Fplus (Thrombosis Risk Panel-Fluorescent) product is a fluorescent kit that provides laboratories with a simple and accurate means of routinely testing for the most relevant mutations implicated in the risk of developing venous thromboembolism.

Elucigene TRP-Fplus is intended to the simultaneous in vitro qualitative detection of the following mutations implicated in the risk of developing venous thromboembolism:

• Factor V Leiden R506Q
• Factor II 20210 G>A  
• MTHFR 677 C>T
• MTHFR 1298 A>C

The test can distinguish between individuals who are heterozygous and homozygous for the all the above mutations.

The method employed by the Elucigene TRP-Fplus kit uses fluorescent ARMS allele specific amplification technology, which detects point mutations, insertions or deletions in the DNA. Selection of appropriate oligonucleotides allows specific mutant or normal DNA sequences to be amplified and detected.